BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bordeaux Neurocampus - ECPv4.9.10//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bordeaux Neurocampus
X-ORIGINAL-URL:https://www.bordeaux-neurocampus.fr
X-WR-CALDESC:Évènements pour Bordeaux Neurocampus
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20231026T103000
DTEND;TZID=Europe/Paris:20231026T103000
DTSTAMP:20260410T103824
CREATED:20231003T095003Z
LAST-MODIFIED:20231012T124148Z
UID:162854-1698316200-1698316200@www.bordeaux-neurocampus.fr
SUMMARY:Impromptu seminar - Franck Molina
DESCRIPTION:Venue: CGFB \n\n©Cyril FRESILLON / Sys2Diag / CNRS Photothèque\nFranck Molina\nSys2Diag UMR9005 CNRS / ALCEN\,\nMontpellier \nInvited by David Perrais (IINS) \nTitle\nSynthetic biology : Non-Living Biomachines design for next generation medical diagnostic \nAbstract\nCOVID-19 crisis showed us that research must adapt hit practices to face the pandemics challenges. EasyCOV rapid salivary covid test is an example of such public-private and inter-disciplinary cooperation. Current evolutions in medical practices induce a change of paradigm with the convergence of diagnosis and therapy\, going to precision medicine and “theranostics”. One can observe the new role of biomarkers in biomedical and therapeutic applications\, for instance in the development of molecular multiplex biosensors (nucleic acid\, proteins\, and metabolites). In addition\, there is an increasing interest for point-of-care (POC) and of home monitoring/testing technologies devoted to probe patient parameters in his direct environment. The obvious constraints for such a kind of new clinical practices are simplification\, drastic cost reduction while keeping high performances. Within this context\, synthetic biology provides new opportunities to develop a novel generation of biological biosensors able to perform multiplexed biomarkers detection\, simple computation and returning simplified relevant results 1) In order to design robust synthetic biological biosensor systems reliable in a clinical context and based on biochemical circuits\, we developed an original methodology ensuring biochemical implementation of logical tasks within nonliving vesicles so called “biomachines”. This methodology covers in silico design\, simulation\, microfluidics production and clinical validation on human samples 2). It ends up in very simple diagnostic assay like for instance the new insulin-resistance assay\, which is also quick and easy to run out of a laboratory and at very low cost. \nKey publications\n\n1. Courbet A\, Renard E\, Molina F. Bringing next-generation diagnostics to the clinic through synthetic biology. EMBO Mol Med. 2016;8(9):987-91. \n2. Courbet A\, Amar P\, Fages F\, Renard E\, Molina F. Computer-aided biochemical programming of synthetic microreactors as diagnostic devices. Mol Syst Biol. 2018;14(6):e8441. \n3. F Santos Schneider\, Amar P\, A Bahri\, J Espeut\, M Alali\, F. Fages\, F. Molina\,  Biomachines For Medical Diagnosis. Advanced Materials Letters\, VBRI Press\, 2020\, 11 (4)\, pp.1-5. ⟨10.5185/amlett.2020.041499⟩. ⟨hal-03059916⟩ DOI : 10.5185/amlett.2020.041499 \n
URL:https://www.bordeaux-neurocampus.fr/event/seminar-franck-molina/
CATEGORIES:A la une,Pour les scientifiques,Séminaire Impromptu
END:VEVENT
END:VCALENDAR